Literature DB >> 9696378

Gene therapy of neoplastic meningosis.

F D Vrionis1.   

Abstract

Gene therapy of neoplastic meningosis is a promising new approach that relies on introduction of 'suicide' genes into cancer cells. The most commonly used gene has been the herpes virus thymidine kinase gene (HSV-tk) which has been delivered to cancer cells via retroviral or adenoviral vectors. A bystander cytocidal effect to non-transduced tumor cells has been documented and is dependent upon intercellular communication via gap junctions. A variety of gene therapy approaches using the HSV-tk system have been used in experimental models of neoplastic meningosis with promising results. Optimizing vector design and bystander cytotoxicity is a prerequisite for successful gene therapy in patients with neoplastic meningosis.

Entities:  

Mesh:

Year:  1998        PMID: 9696378     DOI: 10.1023/a:1005900807890

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy.

Authors:  N Shinoura; L Chen; M A Wani; Y G Kim; J J Larson; R E Warnick; M Simon; A G Menon; W L Bi; P J Stambrook
Journal:  J Neurosurg       Date:  1996-05       Impact factor: 5.115

2.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Authors:  W L Bi; L M Parysek; R Warnick; P J Stambrook
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

3.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

4.  Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival.

Authors:  S H Chen; K Kosai; B Xu; K Pham-Nguyen; C Contant; M J Finegold; S L Woo
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

5.  Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V).

Authors:  J Pavlovic; M Nawrath; R Tu; T Heinicke; K Moelling
Journal:  Gene Ther       Date:  1996-07       Impact factor: 5.250

6.  Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors.

Authors:  F L Moolten; J M Wells
Journal:  J Natl Cancer Inst       Date:  1990-02-21       Impact factor: 13.506

7.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells.

Authors:  J J Viola; Z Ram; S Walbridge; E M Oshiro; B Trapnell; J H Tao-Cheng; E H Oldfield
Journal:  J Neurosurg       Date:  1995-01       Impact factor: 5.115

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

10.  The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene.

Authors:  A A Elshami; J C Kucharczuk; D H Sterman; W R Smythe; H C Hwang; K M Amin; L A Litzky; S M Albelda; L R Kaiser
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

View more
  4 in total

Review 1.  Current options for the treatment of neoplastic meningitis.

Authors:  Ilkcan Cokgor; Allan H Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

2.  Leptomeningeal Neoplasms.

Authors:  Lauren E. Abrey
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

Review 3.  Neoplastic meningitis.

Authors:  Ana Aparicio; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 4.  Neoplastic meningitis.

Authors:  Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.